What is Affymetrix Earnings Yield (Joel Greenblatt) %?
Affymetrix's Enterprise Value for the quarter that ended in Dec. 2015 was $847.4 Mil.
Affymetrix's EBIT for the trailing twelve months (TTM) ended in Dec. 2015 was $17.5 Mil. Affymetrix's Earnings Yield (Joel Greenblatt) for the quarter that ended in Dec. 2015 was 2.06%.
The historical rank and industry rank for Affymetrix's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
AFFX's Earnings Yield (Joel Greenblatt) % is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: -2.42 * Ranked among companies with meaningful Earnings Yield (Joel Greenblatt) % only.
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Affymetrix's Forward Rate of Return (Yacktman) % for the quarter that ended in Dec. 2015 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past seven years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Affymetrix Earnings Yield (Joel Greenblatt) % Historical Data
The historical data trend for Affymetrix's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Affymetrix's Earnings Yield (Joel Greenblatt) %
For the Diagnostics & Research subindustry, Affymetrix's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Affymetrix's Earnings Yield (Joel Greenblatt) % Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Affymetrix's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Affymetrix's Earnings Yield (Joel Greenblatt) % falls into.
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Affymetrixs Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2015 is calculated as
Affymetrix's EBIT for the trailing twelve months (TTM) ended in Dec. 2015 adds up the quarterly data reported by the company within the most recent 12 months, which was $17.5 Mil.
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
Affymetrix Earnings Yield (Joel Greenblatt) % Related Terms
Thank you for viewing the detailed overview of Affymetrix's Earnings Yield (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.
Affymetrix Inc was incorporated in California in 1992 and reincorporated in Delaware in 1998. The Company is a provider of life science tools and molecular diagnostic products that enable parallel analysis of biological systems at the gene, protein and cell level. It sells its products to genomic research centers, academic institutions, government and private laboratories, as well as pharmaceutical, diagnostic and biotechnology companies. The Companys operations consist of two reportable segments, Affymetrix Core and eBioscience. Affymetrix Core is divided into three business units with each business unit having its own research, development and marketing groups to better serve customers and respond quickly to the market needs. The three business units that form Affymetrix Core are; Expression, Genetic Analysis and Clinical Applications, and Life Science Reagents. Expression: This business unit develops and markets the Company's GeneChip gene expression products and services, and the QuantiGene line of low-to-mid-plex RNA measurement products; Genetic Analysis and Clinical Applications. This business unit develops and markets the Company's genotyping, such as the Axiom product line and clinical research applications, such as the CytoScan cytogenetics; Life Science Reagents; This business unit develops and sells reagents, enzymes, purification kits and biochemicals used by life science researchers. eBioscience; This reportable segment specializes in the development, manufacturing, marketing and distribution of research tools in the areas of flow cytometry, immunoassays, microscopic imaging and other protein-based analyses. The Company markets and distributes its products directly to customers in North America, Japan and major European markets. The Company is facing competition as existing companies develop new or improved products, and as companies enter the market with new technologies, such as next-generation sequencing. In the highly multiplexed genotyping and gene expression markets, existing competitive technologies include DNA sequencing, which the Company does not offer and is offered by companies such as Illumina, Inc., Life Technologies Corporation and Pacific Biosciences of California, Inc. The Companys operations are subject to complex and stringent environmental, health, safety and other governmental laws and regulations.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
AFFX has been successfully added to your 